Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770 is registered in ClinicalTrials.gov with Therapeutic Advances in Childhood Leukemia Consortium as lead sponsor.

NCT NCT05476770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05476770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Phase
Phase 1
Overall status
Recruiting
Start date
November 11, 2022
Completion date
November 11, 2027
Enrollment
54 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

acute undifferentiated leukemia, all, aml, bpdcn, hematologic malignancy, hodgkin lymphoma, lymphoblastic lymphoma, lymphoma, b-cell, lymphoma, t-cell, mds, mixed phenotype acute leukemia